Facebook
Twitter
LinkedIn
ForwardTitle
Category
Credits
Event date
Cost
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
This is the seventh event in the series, "Creating a successful research program: Combining great mentorship with compelling science and building a diverse and inclusive research environment." This series of presentations with interactive discussions brought to you through a partnership between the National Institute of Neurological Disorders and Stroke (NINDS) and the American Neurological Association (ANA).
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
This is the eighth event in the series, "Creating a successful research program: Combining great mentorship with compelling science and building a diverse and inclusive research environment." This series of presentations with interactive discussions brought to you through a partnership between the National Institute of Neurological Disorders and Stroke (NINDS) and the American Neurological Association (ANA).
- 2.25 AMA PRA Category 1 Credit™
- 2.25 Participation
$99.00
Next-level foundational principles in statistics for the Neurological Researcher.
- 5.75 AMA PRA Category 1 Credit™
- 5.75 Participation
$0.00
A bite-size learning module series designed to close the knowledge gap about the current state of neurogenetics and the applications of genetic testing.The ANA Highlights Neurogenetics program is chaired by Dr. M. Elizabeth Ross, Nathan Cummings Professor and Head, Laboratory of Neurogenetics and Development, Director, Center for Neurogenetics at Weill Cornell Medicine. The ANA Highlights bite-size learning program is chaired by Michelle C. Johansen, MD, PhD, Assistant Professor of Neurology, Cerebrovascular Division at the Johns Hopkins Hospital.
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Participation
$49.00
What does the word Placebo mean to you? Randomized, placebo controlled clinical trials have been the mainstay of clinical science for decades. Physicians, and medical researchers may assume that they understand the underlying concepts of a placebo controlled trial, but automatically assuming that rigorous research equates to placebo controlled trials is inaccurate. In this ANA Highlights, we will talk about placebos, what we can learn from them, as well as situations where alternative study designs should be considered. Watch this 20-minute video to learn more.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
$0.00
The ANA Highlights Gene Therapy program is chaired by 2024 ANA President, Dr. M. Elizabeth Ross, Nathan Cummings Professor and Head, Laboratory of Neurogenetics and Development, Director, Center for Neurogenetics at Weill Cornell Medicine and Dr. Bryan Traynor, Senior Investigator at the National Institute on Aging (NIA) and the National Center for Advancing Translational Sciences (NCATS), where he leads the RNA Therapeutics Laboratory. This course is brought to you by the ANA Education Innovation Committee, currently chaired by Dr. Michelle C.
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
$0.00
This is the sixth event in the series, "Creating a successful research program: Combining great mentorship with compelling science and building a diverse and inclusive research environment." This series of presentations with interactive discussions brought to you through a partnership between the National Institute of Neurological Disorders and Stroke (NINDS) and the American Neurological Association (ANA).
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Participation
$0.00
This course reviews the journey from testing to prognosis to treatment/prevention to advocacy, testing children vs adults, clinical trials, why test, how to find trials, and a review of what treatments are available. Dr. Jennifer L Orthmann-Murphy, Assistant Professor of Neurology and Co-Director of Age Span Fellowship in MS/Neuroinflammatory Disorders at the University of Pennsylvania is the lead for this module.
- 2.00 AMA PRA Category 1 Credit™
- 2.00 Participation
$0.00
The course is an overview of genetic testing research, variants of uncertain significance, role of somatic mosaicism in neurological diseases, the role of big data in tackling brain disorders of children and adults, pharmacogenomics and importance of genetic diversity in research toward clinical utility in neurology. Dr. M. Elizabeth Ross, Nathan Cummings Professor and Head, Laboratory of Neurogenetics and Development, Director, Center for Neurogenetics at Weill Cornell Medicine is the lead for this module.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Participation
$0.00
The course is a primer for the practicing clinician and includes discussion about: the importance of family history and phenotype to accurate genetic diagnosis, e.g., when to order microarrays, disease gene panels, vs. whole exome vs. whole genome sequencing, use of specialized tests (i.e. suspected mosaicism, nucleotide repeat disorders), and pedigree analysis. Dr. Andrea Gropman, Chief of Neurogenetics and Neurodevelopmental Pediatrics and Attending Neurologist at Children’s National is the lead for this module.